News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalix Biotherapeutics, Inc. (PLX) to Review CHMP Opinion for ELELYSO(TM)



6/22/2012 9:31:49 AM

CARMIEL, Israel, June 22, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today the Company has scheduled a conference call and webcast for Friday, June 22, 2012 at 9:00 AM EDT to review the Committee for Medicinal Products for Human Use's (CHMP) opinion for taliglucerase alfa (ELELYSO™), an enzyme replacement therapy for the treatment of Gaucher disease.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES